Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Regulatory
Sort By
Newest First
Sign in
1 / 45
1 / 45
FDA
Boehringer's Zongertinib ReceivesFDA Priority Review for the Treatment of HER2 (ERBB2)- NSCLC
Boehringer Ingelheim Pharmaceuticals, Inc.
PR-02-25-NI-21
Feb 20, 2025
Approval
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences
PR-02-25-NI-16
Feb 19, 2025
Federal Job Cuts
Science Under Siege: The Devastating Consequences of Public Health and Research Cuts
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-25-CL-14
Feb 19, 2025
FDA
Roche Receives FDA 510(k) Clearance for the First Blood Test in the U.S. Measuring Lp(a) in Nolar Units
Roche
PR-01-25-NI-29
Feb 11, 2025
Drug Development
Nektar Therapeutics Receives Fast Track Designation for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
PR-02-25-NI-07
Feb 10, 2025
Announcement
Sano Chemicals Inc Announces Approval to Start Phase 1 MAD Study
Sano Chemicals Inc
PR-01-25-NI-30
Feb 04, 2025
FDA
Clarity Receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in Biochemical Recurrence of Prostate Cancer
Clarity
PR-01-25-NI-25
Jan 24, 2025
FDA
Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65 Powered by AxcynDOT™ Technology
Axcynsis Therapeutics
PR-01-25-NI-19
Jan 16, 2025
Clinical CRO
Regulatory Approval Clears Path for Oncolytics Biotech to Pancreatic Cancer Treatment
Oncolytics Biotech
PR-01-25-NI-18
Jan 16, 2025
Large Molecule
Managing Pharmacovigilance Challenges for Biosimilars
Ivana Lisec, MPharm
PrimeVigilance
PAO-11-24-CL-05
Jan 02, 2025
AI
AI Implementation to Enhance Quality
Seongil Cho; Hyeokgeon Kwon; Kisung Shim
Samsung Biologics
PAO-12-24-CL-5
Dec 13, 2024
FDA
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
HuidaGene Therapeutics
PR-10-24-NI-81
Nov 07, 2024
Clinical Treatment
Eisai Completes Submission to US FDA for LEQEMBI Application for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Eisai
PR-10-24-NI-70
Nov 01, 2024
QbD
Designing Quality into Biomanufacturing
Miguel Carrion; Michelle Kneeland
Tanvex CDMO
PAO-10-24-CL-09
Oct 29, 2024
Clinical Trials
Passion and Understanding Essential for Rare Disease Clinical Trials
Juliet Moritz
Ergomed
PAO-10-24-CL-03
Oct 29, 2024
BIOSECURE Act
Can you discuss the anticipated impacts of the BIOSECURE Act on the biopharmaceutical landscape?
Pharma's Almanac
PAO-11-24-RT-01
Oct 28, 2024
Clinical Trials
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax
PR-10-24-NI-48
Oct 17, 2024
FDA
U.S. Food and Drug Administration
U.S. Food & Drug Administration
PR-10-24-NI-44
Oct 14, 2024
FDA
FDA Approves IMULDOSA, Accord BioPharma's Biosimilar to STELARA, for the Treatment of Chronic Inflammatory Conditions
Accord Biopharma
PR-10-24-NI-43
Oct 14, 2024
FDA
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia
Systimmune, Inc.
PR-10-24-NI-42
Oct 14, 2024
